Treatment of patients with Acute Myeloid Leukemia (AML) undergoing hemodialysis is especially challenging since there are no specific management guidelines for the administration of cytotoxic agents in these patients. Well established chemotherapy protocols may be unsuitable in such cases because of altered drug pharmacokinetics, increased risk for complications, and underlying co-morbidities. In addition, these patients are at an increased risk for complications such as tumor lysis syndrome. Herein, we report the first use of decitabine in a patient on hemodialysis. He presented with a new diagnosis of AML and achieved hematologic remission following the use of induction chemotherapy and maintenance decitabine.
SauerHFugerKBlumensteinM. Modulation of cytotoxicity of cytostatic drugs by hemodialysis in vitro and in vivo. Cancer Treat Rev1990; 17:293–300.
2.
RegardhCG. Factors contributing to variability in drug pharmacokinetics. IV. Renal excretion. J Clin Hosp Pharm1985; 10:337–49.
3.
SmithGADamonDLRugoHSRiesCALinkerCA. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol1997; 5:833–39.
4.
RavandiFIssaJPGarcia-ManeroG. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer2009; 115:5746.
5.
KantarjianHMIssaJPRosenfeldCS. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer2006; 106:1794–803.
6.
SteensmaDPBaerMRSlackJL. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndrome: The alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol2009; 27: 3842–48.
7.
ChabotGGRivardGEMomparlerRL. Plasma and cerebrospinal fluid pharmacokinetics of 5-aza-2′-deoxycytidine in rabbits and dogs. Cancer Res1983; 43:592–97.
8.
MomparlerRL. Molecular, cellular and animal pharmacology of 5-aza-2′-deoxycytidine. Pharmacol Ther1985; 30:287–99.
9.
MomparlerRL. Pharmacology of 5-aza-2′-deoxycytidine (decitabine). Semin Hematol2005; 42:S9–16.
10.
GarciaJSJainNGodleyLA. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndrome. Onco Targets Ther2010; 10:1–13.
11.
Van GroeningenCJLeyvaAO'BrienAMGallHEPinedoHM. Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res1986; 46:4831–36.
12.
CashenAFShahAKTodtLFisherNDiPersioJ. Pharnacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol2008; 61:759–66.
13.
BattyGNKantarjianHIssaJ-P. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk2010; 10:205–10.
